News Quantified

REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth [Yahoo! Finance]

Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth [Globe and Mail, The (Toronto, Canada)]

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

Regeneron Announces Investor Conference Presentations

1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky [Yahoo! Finance]

0.6%

BEAT

8.5%

BEAT

2.5%

BEAT

0.2%

BEAT

Form 8-K REGENERON PHARMACEUTICAL For: Apr 08

Form 4 REGENERON PHARMACEUTICAL For: Apr 01 Filed by: RYAN ARTHUR F

Form SCHEDULE 13G/A REGENERON PHARMACEUTICAL Filed by: VANGUARD GROUP INC

Form 4 REGENERON PHARMACEUTICAL For: Mar 02 Filed by: RYAN ARTHUR F

Form 4 REGENERON PHARMACEUTICAL For: Feb 19 Filed by: Zoghbi Huda Y

Top News Gainers

3/17 Regeneron Announces Important Advances in Novel COVID-19 Antibody Program 7.4%

11/5 Regeneron Reports Third Quarter 2019 Financial and Operating Results 6.9%

3/3 Regeneron Announces Upcoming Investor Conference Presentations 6.9%

5/8 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00. 6.5%

4/15 Form 4 REGENERON PHARMACEUTICAL For: Apr 13 Filed by: STAHL NEIL 5.5%

4/16 Form 4 REGENERON PHARMACEUTICAL For: Apr 14 Filed by: LAROSA JOSEPH J 5.3%

2/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Citigroup Inc from $420.00 to $540.00. They now have a "buy" rating on the stock. 5.0%

11/8 U.S. company directors compensated more than ever, but now risk backlash [Reuters] 4.9%

10/10 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 4.7%

2/28 Form 4 REGENERON PHARMACEUTICAL For: Feb 26 Filed by: SING GEORGE L 4.5%

Top News Decliners

3/19 Coronavirus Proves Drug Companies To Be Innovators [Forbes] -10.3%

2/27 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -8.6%

3/11 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: YANCOPOULOS GEORGE -7.1%

5/7 Q1/2019 3/31/2019 EPS 4.450 ZacksConsensus 5.240 ActVsEst (0.790) - Miss -6.6%

4/20 Form 4 REGENERON PHARMACEUTICAL For: Apr 16 Filed by: LAROSA JOSEPH J -5.1%

8/14 Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol -4.1%

5/9 Form CT ORDER REGENERON PHARMACEUTICAL -3.5%

4/27 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival -3.5%

4/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $575.00 price target on the stock, up previously from $540.00. -3.3%

3/10 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: GOLDSTEIN JOSEPH L -3.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day